AML
Showing NaN - NaN of 18
Acute Myelogenous Leukemia, AML Trial in Worldwide (Venetoclax, Cytarabine)
Completed
- Acute Myelogenous Leukemia
- AML
-
Kansas City, Kansas
- +8 more
Aug 3, 2022
AML, MDS, ALL, Adult Trial in Hackensack, New York (SOC + TSC-100, SOC + TSC-101, Control)
Recruiting
- AML
- +2 more
- SOC + TSC-100
- +2 more
-
Hackensack, New Jersey
- +1 more
Aug 11, 2022
Hematologic Malignancy, AML, ALL Trial in Australia, United States (Tagraxofusp, Fludarabine, Cytarabine)
Not yet recruiting
- Hematologic Malignancy
- +10 more
- Tagraxofusp
- +8 more
-
Los Angeles, California
- +28 more
Jul 26, 2022
Acute Myeloid Leukemia, MDS, Chronic Myelomonocytic Leukemia Trial in Canada, United States (CFI-400945, Azacitidine,
Recruiting
- Acute Myeloid Leukemia
- +5 more
- CFI-400945
- +2 more
-
Duarte, California
- +7 more
Jul 20, 2022
AML, ALL, MDS Trial in New York (Clofarabine, Fludarabine, Busulfan)
Recruiting
- AML
- +8 more
- Clofarabine
- +5 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center
May 13, 2022
AML Trial in Puerto Rico, United States (Cytarabine (Phase 1 only), Lintuzumab-Ac225, Furosemide (Phase 1 only))
Completed
- AML
- Cytarabine (Phase 1 only)
- +3 more
-
Los Angeles, California
- +16 more
Feb 22, 2022
Acute Myeloid Leukemia, Leukemia, Acute Myeloid, Myeloid Leukemia, Acute Trial in Canada, United States (Iomab-B, Conventional
Active, not recruiting
- Acute Myeloid Leukemia
- +8 more
- Iomab-B
- +2 more
-
Gilbert, Arizona
- +23 more
Feb 22, 2022
AML, MDS Trial in Belgium, United States (NKR-2)
Completed
- AML
- MDS
- NKR-2
-
Aurora, Colorado
- +6 more
Apr 30, 2021
Relapsed/Refractory AML, Relapsed/Refractory ALL, Secondary AML/MDS Trial in Canada, United States (Plerixafor Dose Escalation)
Completed
- Relapsed/Refractory AML
- +5 more
- Plerixafor Dose Escalation
-
Phoenix, Arizona
- +8 more
Sep 5, 2018
AML, CML, MDS Trial in Boston, New York, San Antonio (STA-9090 (ganetespib))
Completed
- AML
- +3 more
- STA-9090 (ganetespib)
-
Boston, Massachusetts
- +2 more
Sep 17, 2014
AML, CML, MDS Trial in New York (CYT107 - Recombinant glycosylated human interleukin 7., rhIL-7 (CYT107))
Completed
- AML
- +2 more
- CYT107 - Recombinant glycosylated human interleukin 7.
- rhIL-7 (CYT107)
-
New York, New YorkMemorial Sloan-Kettering Cancer Institute
Jul 25, 2012